San Diego, CA, United States of America

Androscience Corporation


USPTO Granted Patents = 9

% Expired Patents = 44.4



Forward Citations = 38

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Hui-Kang Wang (9 out of 18 patents)

silverMedal Ching-Yuan Su (7 out of 7 patents)

bronzeMedal Qian Shi (6 out of 13 patents)

4.  Charles C Y Shih (4 out of 4 patents)

5.  Charles C-y Shih (4 out of 6 patents)

6.  Kuo-Hsiung Lee (3 out of 56 patents)

7.  Chawnshang Chang (3 out of 9 patents)

8.  Li Lin (3 out of 3 patents)

9.  Junko Ishida (3 out of 4 patents)

10.  Hironori Ohtsu (3 out of 3 patents)

11.  Hideji Itokawa (3 out of 4 patents)

12.  Charles Shih (1 out of 3 patents)

13.  Toshio Kitamura (1 out of 10 patents)

14.  Toshiyuki Kawashima (1 out of 2 patents)

15.  Masayoshi Oyama (1 patent)


9 patents:

Company Overview
Androscience Corporation is a biopharmaceutical company focused on developing novel treatments for male reproductive health disorders. The company's pipeline includes innovative therapies for conditions such as male infertility and erectile dysfunction. With a strong commitment to research and development, Androscience is dedicated to improving the quality of life for men around the world.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

9 Patents

#580 in San Diego, CA

#7,735 in California

#32,588 in US

San Diego, CA (US)
San Diego, CA, United States of America
Forward Citations = 38

14 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Androscience Corporation. Retrieved from https://idiyas.com/company/androscience

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…